Microbore HPLC method with online microdialysis for measurement of topotecan lactone and carboxylate in murine CSF

Journal of Pharmaceutical Sciences

Volumn 93, Issue 9, 2004, Pages 2284-2295

  Leggas, Markos ^a   Zhuang, Yanli ^a   Welden, Jonathan ^a   Self, Zack ^a   Waters, Christopher M ^b   Stewart, Clinton F ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Chromatography; CSF; Microdialysis; Online injection; Pharmacokinetics; Topotecan

Indexed keywords

CARBOXYLIC ACID; LACTONE; TOPOTECAN;

ACCURACY; ANALYTIC METHOD; ANALYTICAL PARAMETERS; ANALYZER; ANIMAL EXPERIMENT; ARTICLE; BRAIN; CALCULATION; CALIBRATION; CONTROLLED STUDY; DIALYSATE; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DETERMINATION; ELUTION; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; MICRODIALYSIS; MOUSE; NONHUMAN; ONLINE ANALYSIS; SAMPLING;

EID: 4344612797     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20134     Document Type: Article

References (36)

1. Fields AL, Runowicz CD. 2003. Current therapies in ovarian cancer. Cancer Invest 21:148-156.
2. Schiller JH. 2001. Future role of topotecan in the treatment of lung cancer. Oncology 61(Suppl 1):55-59.
3. Copeland LJ, Bookman M, Trimble E. 2003. Clinical trials of newer regimens for treating ovarian cancer: The rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. Gynecol Oncol 90:S1-S7.
4. Furman WL, Stewart CF, Kirstein M, Kepner JL, Bernstein ML, Kung F, Vietti TJ, Steuber CP, Becton DL, Baruchel S, Pratt C. 2002. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: A Pediatric Oncology Group study. J Clin Oncol 20:1617-1624.
5. Athale UH, Stewart C, Kuttesch JF, Moghrabi A, Meyer W, Pratt C, Gajjar A, Heideman RL. 2002. Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol 20: 88-95.
6. Saylors RL III, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, Harris MB, Hayashi R, Vietti TJ. 2001. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study. J Clin Oncol 19:3463-3469.
7. Kushner BH, Cheung NK, Kramer K, Dunkel IJ, Calleja E, Boulad F. 2001. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplant 28:551-556.
8. Park JR, Slattery J, Gooley T, Hawkins D, Lindsley K, Villablanca JG, Matthay KK, Sanders JE. 2000. Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors. Med Pediatr Oncol 35:719-723.
9. Drewinko B, Freireich EJ, Gottlieb JA. 1974. Lethal activity of camptothecin sodium on human lymphoma cells. Cancer Res 34:747-750.
10. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB, Jr., Stewart L. 2002. The mechanism of topoisomerase I poisoning by a camptothecin analog. PNAS 99:15387-15392.
11. Danks MK, Pawlik CA, Whipple DO, Wolverton JS. 1997. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure. Clin Cancer Res 3:1731-1738.
12. Pawlik CA, Houghton PJ, Stewart CF, Cheshire PJ, Richmond LB, Danks MK. 1998. Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays. Clin Cancer Res 4: 1995-2002.
13. Blaney SM, Cole DE, Balis FM, Godwin K, Poplack DG. 1993. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 53:725-727.
14. Sung C, Blaney SM, Cole DE, Balis FM, Dedrick RL. 1994. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res 54:5118-5122.
15. Baker SD, Heideman RL, Crom WR, Kuttesch JF, Gajjar A, Stewart CF. 1996. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol 37: 195-202.
16. Stewart CF, Iacono LC, Chintagumpala M, Kellie S, Ashley D, Zamboni WC, Kirstein M, Fouladi M, Seele LG, Wallace D, Houghton PJ, Gajjar AJ. 2004. Results of a phase II upfront window of pharmacokinetically guided topotecan (TPT) in high-risk medulloblastoma (MB) and supratentorial primitive neuroectodermal tumor (SPNET). J Clin Oncol.
17. Kehr J, Yoshitake T, Wang FH, Wynick D, Holmberg K, Lendahl U, Bartfai T, Yamaguchi M, Hokfelt T, Ogren SO. 2001. Microdialysis in freely moving mice: Determination of acetylcholine, serotonin, and noradrenaline release in galanin transgenic mice. J Neurosci Methods 109:71-80.
18. Warner DL, Burke TG. 1997. Simple and versatile high-performance liquid Chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. J Chromatogr B Biomed Sci Appl 691:161-171.
19. Nicolaysen LC, Pan HT, Justice JB. 1988. Extracellular cocaine and dopamine concentrations are linearly related in rat striatum. Brain Res 456:317-323.
20. Aasmundstad TA, Morland J, Paulsen RE. 1995. Distribution of morphine 6-glucuronide and morphine across the blood-brain barrier in awake, freely moving rats investigated by in vivo microdialysis sampling. J Pharmacol Exp Ther 275:435-441.
21. Paxinos G, Watson C. 1998. The mouse brain in stereotaxic coordinates. San Diego, CA: Academic Press.
22. Hayes KE, Raucci JA, Jr., Gades NM, Toth LA. 2000. An evaluation of analgesic regimens for abdominal surgery in mice. Contemp Top Lab Anim Sci 39:18-23.
23. Zamboni WC, Stewart CF, Thompson J, Santana VM, Cheshire PJ, Richmond LB, Luo X, Poquette C, Houghton JA, Houghton PJ. 1998. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 90:505-511.
24. Zamboni WC, Houghton PJ, Johnson RK, Hulstein JL, Crom WR, Cheshire PJ, Hanna SK, Richmond LB, Luo X, Stewart CF. 1998. Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. J Pharmacol Exp Ther 284:89-94.
25. Zamboni WC, Houghton PJ, Hulstein JL, Kirstein M, Walsh J, Cheshire PJ, Hanna SK, Danks MK, Stewart CF. 1999. Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. Cancer Chemother Pharmacol 43:269-276.
26. Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB. 1994. Clinical pharmacodynamics of continuous infusion topotecan in children: Systemic exposure predicts hematologic toxicity. J Clin Oncol 12:1946-1954.
27. Le Quellec A, Dupin S, Genissel P, Saivin S, Marchand B, Houin G. 1995. Microdialysis probes calibration: Gradient and tissue dependent changes in no net flux and reverse dialysis methods. J Pharmacol Toxicol Methods 33:11-16.
28. de Lange EC, de Boer AG, Breimer DD. 2000. Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv Drug Deliv Rev 45: 125-148.
29. Chourpa I, Millot JM, Sockalingum GD, Riou JF, Manfait M. 1998. Kinetics of lactone hydrolysis in antitumor drugs of camptothecin series as studied by fluorescence spectroscopy. Biochim Biophys Acta 1379:353-366.
30. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH. 1999. The mouse Bcrp1/Mxr/Abcp gene: Amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59:4237-4241.
31. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH. 1999. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 59:4559-4563.
32. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH. 2000. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92:1651-1656.
33. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP. 2001. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7:1028-1034.
34. Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD, Sorrentino BP. 2002. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci USA 99:12339-12344.
35. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, Van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP. 1994. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
36. Schinkel AH, Wagenaar E, Mol CA, Van Deemter L. 1996. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524.